Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Abbott Laboratories's pretax income for the
three
months ended in Jun. 2026 was CHF1,218 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was CHF5,974 Mil.
Abbott Laboratories's pretax margin was 12.10%.
During the past 13 years, Abbott Laboratories's highest Pretax Margin was 19.10%. The lowest was 6.78%. And the median was 15.49%.
During the past 13 years, Abbott Laboratories's highest Pretax Margin was 19.10%. The lowest was 6.78%. And the median was 15.49%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories Pre-Tax Income Related Terms
Abbott Laboratories Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ABT vs SYK, MDT, BSX: Pre-Tax Income Comparison
For the Medical Devices subindustry, Abbott Laboratories's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories Pre-Tax Income vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF5,974 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (XSWX:ABT) has a Pre-Tax Income of CHF5,974 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Abbott Laboratories and its competitors.
Is Abbott Laboratories' Pre-Tax Income too high?
Abbott Laboratories' current Pre-Tax Income is CHF5,974 Mil. Overall, Abbott Laboratories has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Pre-Tax Income compare to SYK and MDT?
Abbott Laboratories' Pre-Tax Income of CHF5,974 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Medical Devices & Instruments company?
A good Pre-Tax Income depends on the Medical Devices & Instruments industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current Pre-Tax Income is CHF5,974 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current Pre-Tax Income of CHF5,974 Mil. The stock's GF Value™ is CHF105.78, compared to a current price of CHF89.00 — trading 15.9% below its estimated fair value. The current Pre-Tax Income is CHF5,974 Mil. Abbott Laboratories' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Pre-Tax Income is CHF5,974 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of CHF89.00 is trading 15.9% below its estimated GF Value™ of CHF105.78.
Key valuation signals for XSWX:ABT:
Pre-Tax Income: CHF5,974 Mil
GF Value™: CHF105.78 vs. price of CHF89.00 (15.9% below fair value)
No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
78GF Score
Get the complete analysis for XSWX:ABT
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABT has been successfully added to your 
